CSF3 and myocardial infarction: The phase III clinical trial Safety and efficacy of SITAgliptin plus Granulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI) randomized 174 patients to either G-CSF and Sitagliptin or placebo after PPCI for MI in a multi-centre, double-blind design.